123 related articles for article (PubMed ID: 24684467)
1. Cost-effectiveness of molecular testing for thyroid nodules with atypia of undetermined significance cytology.
Lee L; How J; Tabah RJ; Mitmaker EJ
J Clin Endocrinol Metab; 2014 Aug; 99(8):2674-82. PubMed ID: 24684467
[TBL] [Abstract][Full Text] [Related]
2. UTILITY OF ULTRASOUND VERSUS GENE EXPRESSION CLASSIFIER IN THYROID NODULES WITH ATYPIA OF UNDETERMINED SIGNIFICANCE.
Villabona CV; Mohan V; Arce KM; Diacovo J; Aggarwal A; Betancourt J; Amer H; Jose T; DeSantis P; Cabral J
Endocr Pract; 2016 Oct; 22(10):1199-1203. PubMed ID: 27409819
[TBL] [Abstract][Full Text] [Related]
3. Qualifiers of atypia in the cytologic diagnosis of thyroid nodules are associated with different Afirma gene expression classifier results and clinical outcomes.
Baca SC; Wong KS; Strickland KC; Heller HT; Kim MI; Barletta JA; Cibas ES; Krane JF; Marqusee E; Angell TE
Cancer Cytopathol; 2017 May; 125(5):313-322. PubMed ID: 28152275
[TBL] [Abstract][Full Text] [Related]
4. Effect of malignancy rates on cost-effectiveness of routine gene expression classifier testing for indeterminate thyroid nodules.
Wu JX; Lam R; Levin M; Rao J; Sullivan PS; Yeh MW
Surgery; 2016 Jan; 159(1):118-26. PubMed ID: 26435428
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness of Diagnostic Lobectomy Versus Observation for Thyroid Nodules >4 cm.
Lee L; Mitmaker EJ; Chabot JA; Lee JA; Kuo JH
Thyroid; 2016 Feb; 26(2):271-9. PubMed ID: 26715288
[TBL] [Abstract][Full Text] [Related]
6. Has Afirma gene expression classifier testing refined the indeterminate thyroid category in cytology?
Yang SE; Sullivan PS; Zhang J; Govind R; Levin MR; Rao JY; Moatamed NA
Cancer Cytopathol; 2016 Feb; 124(2):100-9. PubMed ID: 26422098
[TBL] [Abstract][Full Text] [Related]
7. An independent study of a gene expression classifier (Afirma) in the evaluation of cytologically indeterminate thyroid nodules.
McIver B; Castro MR; Morris JC; Bernet V; Smallridge R; Henry M; Kosok L; Reddi H
J Clin Endocrinol Metab; 2014 Nov; 99(11):4069-77. PubMed ID: 24780044
[TBL] [Abstract][Full Text] [Related]
8. Utility and cost-effectiveness of molecular testing in thyroid nodules with indeterminate cytology.
Labourier E
Clin Endocrinol (Oxf); 2016 Oct; 85(4):624-31. PubMed ID: 27155136
[TBL] [Abstract][Full Text] [Related]
9. Does addition of BRAF V600E mutation testing modify sensitivity or specificity of the Afirma Gene Expression Classifier in cytologically indeterminate thyroid nodules?
Kloos RT; Reynolds JD; Walsh PS; Wilde JI; Tom EY; Pagan M; Barbacioru C; Chudova DI; Wong M; Friedman L; LiVolsi VA; Rosai J; Lanman RB; Kennedy GC
J Clin Endocrinol Metab; 2013 Apr; 98(4):E761-8. PubMed ID: 23476074
[TBL] [Abstract][Full Text] [Related]
10. Calcitonin measurement in the evaluation of thyroid nodules in the United States: a cost-effectiveness and decision analysis.
Cheung K; Roman SA; Wang TS; Walker HD; Sosa JA
J Clin Endocrinol Metab; 2008 Jun; 93(6):2173-80. PubMed ID: 18364376
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of a novel molecular test for cytologically indeterminate thyroid nodules.
Li H; Robinson KA; Anton B; Saldanha IJ; Ladenson PW
J Clin Endocrinol Metab; 2011 Nov; 96(11):E1719-26. PubMed ID: 21865367
[TBL] [Abstract][Full Text] [Related]
12. Usage trends and performance characteristics of a "gene expression classifier" in the management of thyroid nodules: An institutional experience.
Samulski TD; LiVolsi VA; Wong LQ; Baloch Z
Diagn Cytopathol; 2016 Nov; 44(11):867-873. PubMed ID: 27534929
[TBL] [Abstract][Full Text] [Related]
13. Multicenter clinical experience with the Afirma gene expression classifier.
Alexander EK; Schorr M; Klopper J; Kim C; Sipos J; Nabhan F; Parker C; Steward DL; Mandel SJ; Haugen BR
J Clin Endocrinol Metab; 2014 Jan; 99(1):119-25. PubMed ID: 24152684
[TBL] [Abstract][Full Text] [Related]
14. Comparative analysis of diagnostic performance, feasibility and cost of different test-methods for thyroid nodules with indeterminate cytology.
Sciacchitano S; Lavra L; Ulivieri A; Magi F; De Francesco GP; Bellotti C; Salehi LB; Trovato M; Drago C; Bartolazzi A
Oncotarget; 2017 Jul; 8(30):49421-49442. PubMed ID: 28472764
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of Gene Expression Classifier Testing of Indeterminate Thyroid Nodules Utilizing a Real Cohort Comparator.
Shapiro S; Pharaon M; Kellermeyer B
Otolaryngol Head Neck Surg; 2017 Oct; 157(4):596-601. PubMed ID: 28828911
[TBL] [Abstract][Full Text] [Related]
16. Nodule size is an independent predictor of malignancy in mutation-negative nodules with follicular lesion of undetermined significance cytology.
Mehta RS; Carty SE; Ohori NP; Hodak SP; Coyne C; LeBeau SO; Tublin ME; Stang MT; Johnson JT; McCoy KL; Nikiforova MN; Nikiforov YE; Yip L
Surgery; 2013 Oct; 154(4):730-6; discussion 736-8. PubMed ID: 24074409
[TBL] [Abstract][Full Text] [Related]
17. Atypia of undetermined significance in thyroid fine-needle aspiration cytology: prediction of malignancy by US and comparison of methods for further management.
Lee KH; Shin JH; Oh YL; Hahn SY
Ann Surg Oncol; 2014 Jul; 21(7):2326-31. PubMed ID: 24566858
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of using a molecular diagnostic test to improve preoperative diagnosis of thyroid cancer.
Najafzadeh M; Marra CA; Lynd LD; Wiseman SM
Value Health; 2012 Dec; 15(8):1005-13. PubMed ID: 23244801
[TBL] [Abstract][Full Text] [Related]
19. Follow-up of atypia and follicular lesions of undetermined significance in thyroid fine needle aspiration cytology.
Dincer N; Balci S; Yazgan A; Guney G; Ersoy R; Cakir B; Guler G
Cytopathology; 2013 Dec; 24(6):385-90. PubMed ID: 23078633
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of fine-needle aspiration cytology (FNAC) and watchful observation for incidental thyroid nodules.
Wong CKH; Liu X; Lang BHH
J Endocrinol Invest; 2020 Nov; 43(11):1645-1654. PubMed ID: 32307641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
